Investments · Pharmaceuticals (drug development)
SoftBank Vision Fund leads $1.1 billion investment in Roivant Sciences
- Investor
- SoftBank Vision Fund (SoftBank Group) (Tokyo)
- In
- Roivant Sciences, Basel, Switzerland
- Value
- $1.1B equity round
- Status
- Announced on August 9, 2017; the round has closed.
- Date
- 2017-08-09
SoftBank Vision Fund led a $1.1 billion equity investment in Roivant Sciences, a drug developer founded in 2014. Roivant is headquartered in Basel, Switzerland, but operates heavily in the US from New York. Existing shareholders also took part.
Why it matters
The investment backed Roivant's model of licensing drug candidates from other companies and developing them in separate subsidiaries.
Use of the money
The investment was intended to speed up the launch of new Roivant subsidiaries, which Roivant said could be in biopharma or in other fields. Roivant works with drug companies and universities to move medicines to patients quickly across several disease areas.
Roivant's base
Roivant was founded in 2014. Its headquarters are in Basel, Switzerland, while much of its work is run from New York. The round included participation from existing shareholders, and the company's valuation was not disclosed.
Sources
Kakehashi M&A News home
